Glax­o­SmithK­line poach­es Pfiz­er's vi­ral vac­cines lead in rush to cap­i­tal­ize on fu­ture of mR­NA

Glax­o­SmithK­line has ap­point­ed Philip Dor­mitzer, for­mer­ly chief sci­en­tif­ic of­fi­cer of Pfiz­er’s vi­ral vac­cines unit, as its newest glob­al head of vac­cines R&D, look­ing to lever­age one of the lead­ing minds be­hind Pfiz­er and BioN­Tech’s RNA col­lab­o­ra­tion that led to Covid-19 jab Comir­naty, the British drug gi­ant said Tues­day.

Dor­mitzer had been with Pfiz­er for a lit­tle more than six years, join­ing up af­ter a sev­en-year stint with No­var­tis, where he reached the role of US head of re­search and head of glob­al vi­rol­o­gy for the com­pa­ny’s vac­cines and di­ag­nos­tics unit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER